Skip to content Galleri® Cancer Testing is an advanced blood test designed to screen for multiple types of cancer before symptoms appear. This innovative test looks for signals associated with cancer in the blood, helping detect cancers that are often difficult to identify early through routine screenings. It offers a convenient and minimally invasive way to check for cancer, requiring only a simple blood draw rather than imaging or invasive procedures. By detecting cancer signals earlier, this test supports more timely diagnosis, which can improve treatment options and outcomes for patients.
By analyzing tiny fragments of DNA that are shed into the bloodstream by cancer cells, Galleri® can identify potential cancer signals across many different cancer types. Its goal is to provide a broader understanding of a person’s health and enable earlier medical intervention when treatment may be most effective. The test uses advanced genomic technology to detect subtle changes in cell-free DNA that may indicate the presence of cancer, even when no symptoms are present. This powerful insight allows healthcare providers to take proactive steps toward diagnosis and treatment, giving patients more control over their long-term health.
Galleri® is a multi-cancer early detection blood test developed by Grail, a healthcare company focused on transforming cancer care through early detection. With a single blood draw, the test uses next-generation sequencing and advanced machine learning to identify cancer-associated signals and predict where in the body those signals may have originated. This innovative approach allows for earlier insights into potential cancers, supporting faster and more targeted follow-up testing.
More than 50 types of cancer are screened, including many without recommended screening methods. The method analyzes methylation patterns in cell-free DNA to detect cancer. If a cancer signal is detected, the test provides information that can help guide healthcare professionals to the most likely location of the cancer for further diagnostic evaluation. It is intended to complement, not replace, standard screenings such as mammograms, colonoscopies, and other age-appropriate tests.
Through a single blood test, it can detect molecular signals that may indicate the presence of cancer even before symptoms appear, making it one of the most advanced and comprehensive tools for early cancer detection. It is designed to detect signals associated with cancers such as:
This broad range of detection makes Galleri® one of the most comprehensive multi-cancer screening tools available.
Galleri® Cancer Testing may be appropriate for adults who want to take a proactive approach to their health, particularly those with:
A family history of cancer
Increased risk factors for cancer due to age, genetics, or lifestyle
A strong interest in early detection and preventive care
It is most beneficial for adults over 50 years old or those with heightened cancer risks to undergo Galleri® testing. By detecting cancer signals early, Galleri® helps support timely diagnosis and potentially better outcomes.
Galleri® is a screening tool and does not diagnose cancer. If a cancer signal is detected, additional diagnostic testing is recommended to confirm the presence of cancer. A negative result means that no cancer signal was detected at the time of testing, but it does not completely rule out cancer.
The Galleri® test is designed to be used alongside routine screenings, not as a replacement for them. All results should be interpreted by a qualified healthcare provider, who can guide the next steps if follow-up evaluation is needed.
